ID   MGH-U3
AC   CVCL_9827
SY   MGHU3; MG-HU-3; MGH-U3 (RN); RN
DR   BTO; BTO:0006287
DR   cancercelllines; CVCL_9827
DR   Cosmic; 928825
DR   Cosmic; 1016886
DR   Cosmic; 1068090
DR   Cosmic; 1285123
DR   Cosmic; 1286013
DR   Cosmic; 1302361
DR   Cosmic; 1927290
DR   Cosmic; 1938479
DR   Cosmic; 2037951
DR   Cosmic; 2050458
DR   Cosmic; 2686110
DR   GEO; GSM136255
DR   GEO; GSM1374672
DR   GEO; GSM1374673
DR   GEO; GSM1574573
DR   Wikidata; Q54905462
RX   PubMed=4027986;
RX   PubMed=8873383;
RX   PubMed=16885334;
RX   PubMed=19802009;
RX   PubMed=23401075;
RX   PubMed=24018021;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25997541;
RX   PubMed=27270441;
RX   PubMed=29732388;
WW   https://www.synapse.org/UC25
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Unspecified (PubMed=19802009).
CC   Sequence variation: Mutation; HGNC; 13726; KMT2C; Simple; p.Arg4139Ter (c.12415C>T); ClinVar=VCV000975272; Zygosity=Homozygous (PubMed=27270441).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=27270441
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 9
ST   D5S818: 11,13
ST   D7S820: 8
ST   TH01: 7,8
ST   TPOX: 8,12
ST   vWA: 14
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=4027986;
RA   Lin C.-W., Lin J.C., Prout G.R. Jr.;
RT   "Establishment and characterization of four human bladder tumor cell
RT   lines and sublines with different degrees of malignancy.";
RL   Cancer Res. 45:5070-5079(1985).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182;
RA   Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J.,
RA   Carrato A., Tardon A., Serra C., Real F.X.;
RT   "PIK3CA mutations are an early genetic alteration associated with
RT   FGFR3 mutations in superficial papillary bladder tumors.";
RL   Cancer Res. 66:7401-7404(2006).
//
RX   PubMed=19802009; DOI=10.1038/onc.2009.315;
RA   Askham J.M., Platt F.M., Chambers P.A., Snowden H., Taylor C.F.,
RA   Knowles M.A.;
RT   "AKT1 mutations in bladder cancer: identification of a novel oncogenic
RT   mutation that can co-operate with E17K.";
RL   Oncogene 29:150-155(2010).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K.,
RA   Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//